Putting over 200 years of legal experience and innovation to work today.

Cadwalader Represents Salix Pharmaceuticals in Its Pending Acquisition by Valeant Pharmaceuticals

Salix, a leading U.S. specialty pharmaceutical company, agreed to be acquired by Valeant for $158.00 per share, or a total enterprise value of approximately $14.5 billion.

Cadwalader News

SDX™ Protocol

Introducing a new approach to shareholder-director engagement.

Cadwalader Subscription Center